All In Biotech

Drug Trial Radar · NCT07620574

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

May 31, 2030

Study completion May 31, 2030

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Conditions

  • Cancer
  • Renal Cell Carcinoma (RCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Differentiated Thyroid Cancer (DTC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Colorectal Cancer
  • Prostate Cancer

Interventions

  • CabozantinibDrug

    Administered as specified in the parent study.

  • ZanzalintinibDrug

    Administered as specified in the parent study.

  • AtezolizumabDrug

    Administered as specified in the parent study.

  • NivolumabDrug

    Administered as specified in the parent study.

  • AbirateroneDrug

    Administered as specified in the parent study.

  • PrednisoneDrug

    Administered as specified in the parent study.

  • EnzalutamideDrug

    Administered as specified in the parent study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • New York Cancer and Blood Specialists

    Bay Shore, New York

  • Greater Dayton Cancer Center

    Kettering, Ohio

  • The West Clinic

    Memphis, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.